Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E95.63 EPS (ttm)0.70 Insider Own2.70% Shs Outstand101.40M Perf Week-1.20%
Market Cap6.74B Forward P/E- EPS next Y-0.50 Insider Trans-21.10% Shs Float97.88M Perf Month37.00%
Income68.00M PEG13.05 EPS next Q-0.07 Inst Own69.00% Short Float14.27% Perf Quarter125.75%
Sales168.80M P/S39.92 EPS this Y205.90% Inst Trans-0.62% Short Ratio7.19 Perf Half Y151.27%
Book/sh2.57 P/B25.86 EPS next Y-121.90% ROA20.00% Target Price66.57 Perf Year349.05%
Cash/sh2.55 P/C26.05 EPS next 5Y7.33% ROE32.20% 52W Range10.41 - 73.72 Perf YTD435.10%
Dividend- P/FCF41.86 EPS past 5Y20.60% ROI24.90% 52W High-9.85% Beta2.02
Dividend %- Quick Ratio2.70 Sales past 5Y295.20% Gross Margin- 52W Low538.42% ATR4.65
Employees134 Current Ratio2.70 Sales Q/Q283.20% Oper. Margin36.30% RSI (14)62.77 Volatility5.57% 8.27%
OptionableYes Debt/Eq0.00 EPS Q/Q194.90% Profit Margin40.30% Rel Volume0.80 Prev Close67.32
ShortableYes LT Debt/Eq0.00 EarningsNov 25 AMC Payout0.00% Avg Volume1.94M Price66.46
Recom1.80 SMA209.55% SMA5042.28% SMA200119.27% Volume1,557,370 Change-1.28%
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Dec-13-19 06:12PM  Live Nation Entertainment, Zebra Technologies, STERIS Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire
07:30AM  Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors Business Wire
Dec-11-19 03:46PM  Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ? Insider Monkey
07:30AM  Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Business Wire
Dec-06-19 04:01PM  Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million Business Wire
Dec-04-19 06:00AM  Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
Dec-03-19 04:58PM  Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT Thomson Reuters StreetEvents +8.42%
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
06:55AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Dec-02-19 04:48PM  This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering Investor's Business Daily -13.26%
04:05PM  Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock Business Wire
02:57PM  7 Exciting Biotech Stocks to Buy Now InvestorPlace
Nov-29-19 01:23PM  This Biotech With 488% Growth In 2019 Just Gained A Price-Target Boost Investor's Business Daily +5.78%
09:52AM  Biotech Arrowhead Stocks Surge Will Continue, Analyst Says Barrons.com
Nov-28-19 08:07AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Nov-27-19 07:26AM  The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
04:55AM  Arrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their Models Simply Wall St.
Nov-26-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences Business Wire +18.79%
Nov-25-19 04:00PM  Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results Business Wire +15.83%
10:27AM  Novartiss Deal for Medicines Company Is Good News for 2 More Stocks Barrons.com
Nov-18-19 09:32AM  Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019 Business Wire
Nov-15-19 07:30AM  Arrowhead Pharmaceuticals Announces Planned Management Transition Business Wire
Nov-13-19 02:12PM  Arrowhead Shares Are Still Alerting Big Buy Signals Investopedia +7.15%
Nov-11-19 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results Business Wire
06:29AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Nov-08-19 04:13PM  Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock Investor's Business Daily +6.31%
08:00AM  Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 Business Wire
Nov-06-19 06:38AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Oct-31-19 12:15PM  Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference Business Wire
06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 08:41AM  Best Growth Stocks for November 2019 Investopedia
Oct-26-19 07:51AM  The Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are Delighted Simply Wall St.
Oct-23-19 01:25PM  Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Oct-18-19 04:38PM  Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout Investor's Business Daily
11:10AM  Arrowhead Pharmaceuticals Is Flying Higher on the Charts TheStreet.com
07:30AM  Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Oct-04-19 12:11PM  Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex MarketWatch
Oct-02-19 04:15PM  Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Sep-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences Business Wire
Sep-27-19 09:15AM  ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Zacks Small Cap Research
Sep-20-19 04:00PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
10:19AM  Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Paid Enough Relative To Peers? Simply Wall St.
Sep-16-19 03:00AM  Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3 Business Wire
Sep-09-19 06:51AM  Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar? Zacks -8.92%
Sep-08-19 07:28PM  Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August Motley Fool
Aug-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences Business Wire
Aug-29-19 04:21PM  Why This Newly Profitable Biotech Stock Is Flirting With A Breakout Investor's Business Daily
11:02AM  Arrowhead Pharmaceuticals and three other stocks to watch MarketWatch
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
07:30AM  Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection Business Wire
Aug-21-19 12:37PM  Arrowhead Pharmaceuticals: Buy at the High? Motley Fool
Aug-19-19 11:44AM  Arrowhead Pharma Shares Quietly See Big Buy Demand Investopedia +8.11%
Aug-15-19 11:59AM  Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful? Simply Wall St.
09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
Aug-12-19 06:10AM  Edited Transcript of ARWR earnings conference call or presentation 5-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 07:30AM  Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Aug-06-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
06:00AM  What You'll Want to Know About Arrowhead Pharmaceuticals' Q3 Update Motley Fool
Aug-05-19 11:23PM  Arrowhead Research Corp (ARWR) Q3 2019 Earnings Call Transcript Motley Fool -6.46%
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results Business Wire
Jul-24-19 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results Business Wire
Jul-16-19 04:00PM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3 Business Wire
Jul-10-19 07:27AM  How Does Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Affect Your Portfolio Volatility? Simply Wall St.
Jul-08-19 07:30AM  Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference Business Wire
Jun-28-19 04:31PM  Highly Rated Biotech Downgraded After Breaking Out And Running 39% Investor's Business Daily -8.05%
07:32AM  The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
06:45AM  Arrowhead Pharma Heads Down Midday After Downgrade Investing.com
Jun-27-19 07:30AM  Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Jun-24-19 01:38PM  Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Jun-21-19 06:45PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
07:30AM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3 Business Wire
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-12-19 03:32PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 03:44PM  Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 10:02AM  Read This Before Judging Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) ROE Simply Wall St.
06:30AM  Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May Motley Fool
May-31-19 04:00PM  Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences Business Wire
May-21-19 04:27PM  Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today Motley Fool +12.72%
07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga
May-20-19 05:56PM  Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
03:45PM  ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress Zacks Small Cap Research
May-09-19 01:23AM  Arrowhead Research Corp (ARWR) Q2 2019 Earnings Call Transcript Motley Fool +6.11%
May-08-19 04:06PM  Arrowhead Research: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results Business Wire
02:30PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-02-19 04:05PM  Heres What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences Business Wire
May-01-19 07:06PM  Cramer's lighting round: The quarter won't be good, but buy this stock CNBC
Apr-25-19 03:01PM  Did You Miss Arrowhead Pharmaceuticals's (NASDAQ:ARWR) Impressive 217% Share Price Gain? Simply Wall St.
Apr-24-19 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results Business Wire
07:30AM  Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen Business Wire
Apr-21-19 07:57AM  Revamp at Silence does little to improve investors wellbeing Financial Times
Apr-15-19 07:30AM  Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Apr-12-19 12:45PM  Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress Business Wire
06:00AM  Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress Business Wire
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Mar-29-19 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Mar-27-19 07:35AM  Research Report Identifies Criteo S.A, Ferrari N.V, Freshpet, ServiceMaster Global, CSG Systems International, and Arrowhead Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-22-19 04:16PM  Produce with the most pesticides in your grocery store Yahoo Finance -6.82%
Mar-18-19 07:30AM  Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerDec 13Sale66.7383,3335,560,4891,888,570Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale67.50100,0006,749,6301,971,903Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 03Sale61.5812,033740,9522,071,903Dec 04 06:48 PM
Anzalone Christopher RichardChief Executive OfficerDec 02Sale69.1537,9672,625,5702,083,936Dec 04 06:48 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 05Option Exercise5.1912,64965,648326,185Nov 07 06:45 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Option Exercise7.7537,884293,601351,420Nov 01 07:32 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Sale40.8537,8841,547,378313,536Nov 01 07:32 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Option Exercise5.2056,325292,8902,178,228Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Sale31.8356,3251,792,8252,121,903Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerSep 25Sale28.2520,000565,0002,121,903Sep 27 09:16 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Option Exercise5.1066,645339,8902,208,548Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Sale28.2066,6451,879,2402,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Option Exercise5.1041,755212,9512,183,658Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Sale29.0441,7551,212,5652,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Option Exercise5.104,25021,6752,146,153Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Sale29.004,250123,2502,141,903Sep 24 09:12 PM
PERRY MICHAEL SDirectorSep 11Sale30.0085,0002,550,00036,000Sep 11 08:09 PM
PERRY MICHAEL SDirectorSep 09Sale28.90100,0002,890,000121,000Sep 11 08:09 PM
Ferrari MauroDirectorJun 26Sale27.6117,756490,2431,900Jun 28 07:19 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise4.9435,000172,800313,536Jun 03 06:12 PM
O'Brien PatrickGeneral CounselMay 28Sale24.8830,000746,400203,000May 29 07:01 PM
Anzalone Christopher RichardChief Executive OfficerMay 24Option Exercise2.1349,448105,1102,141,903May 29 06:57 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 21Sale22.0027,071595,562278,536May 22 05:44 PM
Anzalone Christopher RichardChief Executive OfficerApr 03Sale19.3050,000965,0002,092,455Apr 05 06:57 PM
GIVEN BRUCE DChief Operating OfficerMar 01Option Exercise2.0142,50085,425687,106Mar 01 08:42 PM
GIVEN BRUCE DChief Operating OfficerMar 01Sale19.9942,500849,575644,606Mar 01 08:42 PM
GIVEN DOUGLAS BDirectorFeb 26Option Exercise3.9265,000254,570240,130Feb 26 07:32 PM
GIVEN DOUGLAS BDirectorFeb 26Sale19.2565,0001,251,250175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Option Exercise2.0142,50085,425687,106Feb 27 07:08 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Sale18.9842,500806,650644,606Feb 27 07:08 PM
GIVEN DOUGLAS BDirectorFeb 22Sale18.053,00054,150175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Option Exercise2.0142,50085,425687,106Feb 20 08:09 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Option Exercise5.208,00041,600313,607Feb 20 08:12 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Sale18.008,000144,000305,607Feb 20 08:12 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Sale17.9842,500764,150644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 15Sale17.6726,250463,838644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Option Exercise2.0142,50085,425713,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Sale17.0642,500725,050670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Option Exercise2.6211,66730,568825,023Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Sale15.96154,1672,460,995670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Option Exercise2.6211,66730,568859,523Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Sale15.3446,167708,202813,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 05Sale14.4822,500325,800847,856Feb 07 08:35 PM
GIVEN BRUCE DChief Operating OfficerFeb 01Sale13.8528,500394,725870,356Feb 01 07:51 PM
GIVEN BRUCE DChief Operating OfficerJan 23Sale13.1517,500230,125898,856Jan 24 08:53 PM
GIVEN BRUCE DChief Operating OfficerJan 22Sale13.59152,0002,065,680916,356Jan 24 08:53 PM
GIVEN DOUGLAS BDirectorJan 22Sale13.583,00040,740178,130Jan 24 08:46 PM
O'Brien PatrickGeneral CounselJan 18Sale14.4372,0001,038,960233,000Jan 18 07:02 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 17Sale14.5581,8751,191,281305,607Jan 18 07:00 PM
GIVEN BRUCE DChief Operating OfficerJan 14Option Exercise2.9012,66636,7651,111,022Jan 16 08:18 PM
Li ZhenSnr. VP, Chem and Non-Clin DevJan 14Sale14.3440,500580,770201,700Jan 16 08:24 PM
GIVEN BRUCE DChief Operating OfficerJan 14Sale14.4042,666614,3901,068,356Jan 16 08:18 PM
Waddill William D.DirectorJan 11Sale14.778,500125,54546,500Jan 11 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 02Sale11.988,33399,829387,482Jan 03 07:55 PM
GIVEN BRUCE DChief Operating OfficerJan 02Sale11.9820,000239,6001,098,356Jan 03 07:53 PM
GIVEN DOUGLAS BDirectorDec 27Sale12.003,00036,000145,130Dec 28 05:20 PM
Anzalone Christopher RichardChief Executive OfficerDec 19Sale13.9290,0001,252,8001,542,455Dec 21 05:15 PM
open in yahoo | open in reuters | open in google